权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Fusion inhibitors that block host-to-host transmission of SARS-CoV-2

阻止 SARS-CoV-2 宿主间传播的融合抑制剂

基本信息

批准号：
10237600
负责人：
Matteo Porotto
金额：
$ 75.02万
依托单位：
COLUMBIA UNIVERSITY HEALTH SCIENCES
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-08-01 至 2026-07-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10237600
关键词：
2019-nCoV Address Affinity Animals Antiviral Agents Binding Biodistribution Biological Assay COVID-19 COVID-19 pandemic COVID-19 treatment Cell Culture Techniques Cell fusion Cell membrane Cell surface Cells Chiroptera Common Cold Communities Coronavirus Coronavirus Infections Couples Data Development Disease Disease Outbreaks Distal Dominant-Negative Mutation Dose Endosomes Ferrets Glycoproteins Homes for the Aged Hospitals Human Immunologics In Vitro Individual Infection Infection prevention Integration Host Factors Lead Life Lipids Mediating Membrane Membrane Fusion Middle East Respiratory Syndrome Coronavirus Modeling Molecular Molecular Conformation Names Nose Peptide Hydrolases Peptides Play Population Process Prophylactic treatment Proteins Role SARS coronavirus Severe Acute Respiratory Syndrome Severity of illness Surface Testing Therapeutic Intervention Toxic effect Vaccinated Vaccines Viral Virus Virus Diseases World Health Organization Zoonoses base betacoronavirus cell type cytotoxicity design dimer experimental study fundamental research genetic information improved in vivo inhibitor/antagonist monomer novel novel coronavirus pandemic disease pre-clinical preclinical study pressure prevent receptor receptor binding research clinical testing transmission process uptake viral transmission virus genetics

项目摘要

Coronaviruses (CoVs) can cause life-threatening diseases. The recently emerging coronavirus-related illness was named coronavirus disease 2019 (abbreviated “COVID-19”) by the World Health Organization. COVID-19 is caused by SARS-CoV-2. Like its predecessors SARS-CoV and MERS-CoV, SARS-CoV-2 (S-CoV-2) is a betacoronavirus that is thought to have originated in bats. Originally its spread was animal-to-human, but human-to-human transmission is now widespread. No vaccines and treatments for COVID-19 are available, and these are urgently needed to address the outbreak as well as inevitable ongoing infection. Antivirals that target viral entry into the host cell have been proven effective against a wide range of viruses. In this proposal, we will apply the results of our fundamental research to the development of novel peptide inhibitors of SARS- CoV-2 entry. We have designed lipid-conjugated fusion-inhibitory peptides that efficiently inhibit coronavirus infection in in vitro, ex vivo, and in vivo. We propose to synthesize and evaluate novel lipidated peptides that have enhanced efficacy. These inhibitors will be evaluated for antiviral activity against live SARS-CoV-2 virus. Promising candidates will be tested in transmission experiments in a ferret model. This application will determine whether our approach to entry inhibition of SARS-CoV-2 prevents infection in vivo. 1. To optimize antiviral potency of HRC-lipopeptide fusion inhibitors. 2. To pre-clinically evaluate HRC-lipopeptide fusion inhibitors biodistribution, toxicity and protection against SARS-CoV-2 infection or transmission in vivo.

冠状病毒（CoV）可导致危及生命的疾病。最近出现的冠状病毒相关疾病被世界卫生组织命名为2019冠状病毒病（简称“COVID-19”）。COVID-19 是由SARS-CoV-2引起的与其前身SARS-CoV和MERS-CoV一样，SARS-CoV-2（S-CoV-2）是一种被认为起源于蝙蝠的β冠状病毒。最初它是通过动物传播给人类的，人际传播现已普遍。没有针对COVID-19的疫苗和治疗方法，这些都是迫切需要的，以解决疫情以及不可避免的持续感染。抗病毒药物，靶病毒进入宿主细胞已被证明对多种病毒有效。在这项提案中，我们将把我们的基础研究成果应用于开发新的SARS肽抑制剂- 冠状病毒2型进入。我们设计了脂质结合的融合抑制肽，有效抑制冠状病毒体外、离体和体内感染。我们建议合成和评估新的脂化肽，具有增强的功效。将评估这些抑制剂对SARS-CoV-2活病毒的抗病毒活性。有希望的候选人将在雪貂模型的传播实验中进行测试。此应用程序将确定我们抑制SARS-CoV-2进入的方法是否能预防体内感染。 1.优化HRC-脂肽融合抑制剂的抗病毒效力。 2.临床前评价HRC-脂肽融合抑制剂的生物分布、毒性和保护作用抗SARS-CoV-2感染或体内传播。